Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Goethe University
Incyte Corporation
Bristol-Myers Squibb
Swiss Cancer Institute
Bristol-Myers Squibb
Xencor, Inc.
City of Hope Medical Center
Mirati Therapeutics Inc.
Case Comprehensive Cancer Center
Bristol-Myers Squibb
AIO-Studien-gGmbH
Incyte Corporation
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)